Remdesivir-related product liability, medical malpractice and wrongful death claims.

A primer on how The Law Offices of Gregory Krasovsky handle Remdesivir (VEKLURY®) related claims for product liability, medical malpractice and wrongful death.

Remdesivir - https://krasovskylaw.com/remdedsivir.html

If you or a loved one were injured, sustained serious side-effects and complications or died after being administered Remdesivir (VEKLURY®), then please contact our Law Offices by phone or email:

The Law Offices of Gregory Krasovsky
1629 K Street NW, Suite 300
Washington, DC 20006
Tel: +1-202-558-5287
Fax: +1-202-558-5346
Email: krasovsky911@gmail.com
Skype: Krasovsky

Website: www.krasovskylaw.com

Facebook: www.facebook.com/gkrasovsky911

YouTube Channel: https://www.youtube.com/channel/UC6N9WNZiCUmj3FUxqbi6XrA/

Gregory Krasovsky, Member, District of Columbia Bar

***

Remdesivir, sold under the brand name Veklury,[13][14] is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences.[15]

It is administered via injection into a vein.[16][17]

During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.[18]

Remdesivir was originally developed to treat hepatitis C,[19] and was subsequently investigated for Ebola virus disease and Marburg virus infections[20] before being studied as a post-infection treatment for COVID‑19.[21]

Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.[22]

The most common side effect in healthy volunteers is raised blood levels of liver enzymes.[13] The most common side effect in people with COVID‑19 is nausea.[13]

Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating.[23]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[24]
...
COVID-19
Hospitalized patients

Remdesivir was approved for medical use in the United States in October 2020.[58][59][60][105] The U.S. Food and Drug Administration (FDA) approved remdesivir based on the agency's analysis of data from three randomized, controlled clinical trials that included participants hospitalized with mild-to-severe COVID‑19.[60][105] The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc.[60] The FDA approved remdesivir based primarily on evidence from three clinical trials (NCT04280705, NCT04292899, and NCT04292730) of 2043 hospitalized participants with COVID‑19.[105] The trials were conducted at 226 sites in 17 countries including the United States.[105]

In November 2020, the World Health Organization (WHO) updated its guideline on therapeutics for COVID‑19 to include a conditional recommendation against the use of remdesivir, triggered by results from the WHO Solidarity trial.[126][127][128][129] Meanwhile, the Public Health Agency of Canada's COVID‑19 Clinical Pharmacology Task Group recommended that remdesivir only be administered to hospitalized patients as part of a randomized controlled trial due to limited information on risks and benefits.[130]

In January 2022, the Canadian component of the WHO Solidarity Trial reported that in-hospital people with COVID‑19 treated with remdesivir had 17% lower relative risk of death (18.7% versus 22.6% death rates) and 47% reduced relative risk for needing oxygen and mechanical ventilation (8.0% versus 15.0%) compared to people receiving standard-of-care treatments.[131]

In September 2022, the WHO updated their guidelines to recommend use of remdesivir for both non-hospitalized and hospitalized patients.[132] This was based on final results from the SOLIDARITY trial that showed a reduction in mortality or progression to mechanical ventilation for non-ventilated patients.

https://en.wikipedia.org/wiki/Remdesivir

***